Suzhou, China, and Gembloux, Belgium – May 19, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life’s strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Plaisance, Sky9 Capital, Yunion, as well as other renowned shareholders.

Chengdu, China – April 8, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. The Company will have a poster presentation.

Chengdu, China – January 12, 2026 – Full-Life Technologies (“Full-Life”), a fully-integrated global radiopharmaceutical company today congratulates its partner SK Biopharmaceuticals Co., Ltd. (“SK Biopharmaceuticals”) on receiving the U.S. Food and Drug Administration (“FDA”) approval of the Phase 1 Investigational New Drug (“IND”) for its radiopharmaceutical therapeutic candidate SKL35501 and imaging agent SKL35502. The therapeutic candidate SKL35501 was in-licensed by SK Biopharmaceuticals from Full-Life in July 2024. The imaging agent SKL35502 utilizes the same NTSR1 target as SKL35501.

Chengdu, China, and Gembloux, Belgium – September 30, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of US$77 million financing, comprised of close to US$50 million Series C equity and US$27 million debt financing. This financing will advance development of the Company's radiopharmaceutical pipeline worldwide and manufacturing capabilities in Belgium.

Shanghai, China, and Gembloux, Belgium – September 25, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the 38th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Barcelona, Spain from October 4 to 8, 2025. The Company has been selected to deliver two Top-Rated Oral Presentations ("TROP") based on accepted abstracts. In addition, the Company will host an exhibition booth, and an e-poster will be displayed at the congress.